Zealand Pharma's CEO Adam Steensberg weighs in on early-stage trials of its obesity drug contender and talks down takeover ...

The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...

Atlas Venture and Bain Capital Life Sciences are making their next bet in the buzzy obesity field, launching a new startup ...

Therapies that deliver hydrogen sulfide to cells could one day become the basis of new treatments for obesity and related ...

Giving older Americans access to weight-loss medicines through the US Medicare program would cost $35 billion over nine years ...

The race to supply obesity drugs is so competitive that one early-stage startup is already striking a deal for commercial ...

New-generation anti-obesity drug Wegovy, made by the same company that created Ozempic, is now available in France – but it ...

As part of our series In Good Health, we discuss these new medications and the falling rate of obesity.

Ilant estimates that behavioral therapy can help many people lose up to 5% of their weight, anti-obesity medications can help ...

Allowing Medicare to cover anti-obesity medications would drive up federal spending by about $35 billion on net between 2026 and 2034, according to ...

John M. Burke, MD, examines how new obesity treatments, such as GLP-1 agonists, might influence future cancer rates.